Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),[ml] / [kg·min],4.0,268,DB01412,Theobromine
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,4.2,269,DB01412,Theobromine
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,2.4,270,DB01412,Theobromine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3863,DB01412,Theobromine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3864,DB01412,Theobromine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3865,DB01412,Theobromine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3866,DB01412,Theobromine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3867,DB01412,Theobromine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3868,DB01412,Theobromine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3869,DB01412,Theobromine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3870,DB01412,Theobromine
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],3.83,3871,DB01412,Theobromine
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.14,3872,DB01412,Theobromine
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],5.09,3873,DB01412,Theobromine
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.41,3874,DB01412,Theobromine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.07,6247,DB01412,Theobromine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.20,6248,DB01412,Theobromine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],0.93,6249,DB01412,Theobromine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.20,6250,DB01412,Theobromine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],3.11,6251,DB01412,Theobromine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],4.14,6252,DB01412,Theobromine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.61,6253,DB01412,Theobromine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.39,6254,DB01412,Theobromine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,6.2,6255,DB01412,Theobromine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,7.2,6256,DB01412,Theobromine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,4.1,6257,DB01412,Theobromine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,3.1,6258,DB01412,Theobromine
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.44,6259,DB01412,Theobromine
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.63-0.72,6260,DB01412,Theobromine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.77,6261,DB01412,Theobromine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.79,6262,DB01412,Theobromine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.18,6263,DB01412,Theobromine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.06,6264,DB01412,Theobromine
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,5.5,7301,DB01412,Theobromine
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,12.7,7302,DB01412,Theobromine
,1474168,area,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13761,DB01412,Theobromine
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13762,DB01412,Theobromine
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],0.15,13763,DB01412,Theobromine
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],1438,13764,DB01412,Theobromine
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],2864,13765,DB01412,Theobromine
,22824731,runtime,The plasma samples were extracted by liquid-liquid extraction with ethyl acetate and separated on Shim-pack XR-ODS II column by a gradient elution within a runtime of 8.0 min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),min,8.0,17333,DB01412,Theobromine
,22824731,flow rate,The mobile phase consisted of A (0.1% formic acid in acetonitrile) and B (0.1% formic acid in water) at a flow rate of 0.4 ml/min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ml] / [min],0.4,17334,DB01412,Theobromine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],"10-10,000",17335,DB01412,Theobromine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],2.0-2000,17336,DB01412,Theobromine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],1.0-1000,17337,DB01412,Theobromine
,1517286,lowest detectable concentration,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),[ng] / [ml],25,26845,DB01412,Theobromine
,1517286,recovery,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),%,85,26846,DB01412,Theobromine
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],485,30790,DB01412,Theobromine
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],646,30791,DB01412,Theobromine
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],735,30792,DB01412,Theobromine
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],781,30793,DB01412,Theobromine
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.90,30794,DB01412,Theobromine
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.66,30795,DB01412,Theobromine
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.31,30796,DB01412,Theobromine
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.32,30797,DB01412,Theobromine
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,3.8,30798,DB01412,Theobromine
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.9,30799,DB01412,Theobromine
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.9,30800,DB01412,Theobromine
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.7,30801,DB01412,Theobromine
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.93,30802,DB01412,Theobromine
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.23,30803,DB01412,Theobromine
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.39,30804,DB01412,Theobromine
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.23,30805,DB01412,Theobromine
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,11991,30806,DB01412,Theobromine
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,8823,30807,DB01412,Theobromine
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,8275,30808,DB01412,Theobromine
,25700100,clearance,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),[ml] / [kg·min],0.95,32052,DB01412,Theobromine
,25700100,elimination half-life,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),h,17.63,32053,DB01412,Theobromine
,2178853,elimination half-life,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),h,2.12,34572,DB01412,Theobromine
,2178853,elimination half-life,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),h,0.83,34573,DB01412,Theobromine
,2178853,plasma clearance,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),[l] / [h·kg],1.44,34574,DB01412,Theobromine
,2178853,plasma clearance,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),[l] / [h·kg],3.62,34575,DB01412,Theobromine
,2178853,absolute bioavailability,"After oral administration of a 400 mg sustained-released tablet, absolute bioavailability of pentoxifylline increased in cirrhotic patients (0.71 +/- 0.24 versus 0.33 +/- 0.13, p less than 0.01).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),,0.71,34576,DB01412,Theobromine
,2178853,absolute bioavailability,"After oral administration of a 400 mg sustained-released tablet, absolute bioavailability of pentoxifylline increased in cirrhotic patients (0.71 +/- 0.24 versus 0.33 +/- 0.13, p less than 0.01).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),,0.33,34577,DB01412,Theobromine
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB01412,Theobromine
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB01412,Theobromine
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB01412,Theobromine
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB01412,Theobromine
,9816047,area under the plasma concentration versus time curve,The median (range) area under the plasma concentration versus time curve for thioTEPA was 29.4 microM/h (26. 2-40.5) and for TEPA was 16.3 microM/h (9.2-21.7 microM-h).,"Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μM] / [h],29.4,53282,DB01412,Theobromine
,9816047,area under the plasma concentration versus time curve,The median (range) area under the plasma concentration versus time curve for thioTEPA was 29.4 microM/h (26. 2-40.5) and for TEPA was 16.3 microM/h (9.2-21.7 microM-h).,"Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μM] / [h],16.3,53283,DB01412,Theobromine
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μg] / [ml],1.2,53284,DB01412,Theobromine
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μg] / [ml],4.0,53285,DB01412,Theobromine
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),,0.4,53286,DB01412,Theobromine
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),,2.9,53287,DB01412,Theobromine
,20045386,Recoveries,Recoveries for caffeine and theobromine ranged from 114 to 118% and 99 to 105% at concentration levels of 10 and 300 micromol L(-1).,"Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045386/),%,114 to 118,53899,DB01412,Theobromine
,20045386,Recoveries,Recoveries for caffeine and theobromine ranged from 114 to 118% and 99 to 105% at concentration levels of 10 and 300 micromol L(-1).,"Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045386/),%,99 to 105,53900,DB01412,Theobromine
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],9.2,56959,DB01412,Theobromine
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],7.8,56960,DB01412,Theobromine
,9430774,half-life of elimination (t1/2 beta),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),h,1.44,56961,DB01412,Theobromine
,9430774,volume of distribution (Vdarea),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[l] / [kg],0.94,56962,DB01412,Theobromine
,17310264,K(i),"SCH58261 was the most potent antagonist of the human A2A with a K(i) value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K(i) value of 1.2 nM.","Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310264/),nM,4,64151,DB01412,Theobromine
,17310264,K(i),"SCH58261 was the most potent antagonist of the human A2A with a K(i) value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K(i) value of 1.2 nM.","Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310264/),nM,1.2,64152,DB01412,Theobromine
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB01412,Theobromine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.03,69860,DB01412,Theobromine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.05,69861,DB01412,Theobromine
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,9.68,69862,DB01412,Theobromine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.08,69863,DB01412,Theobromine
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,6.84,69864,DB01412,Theobromine
,10478991,bioavailability,The bioavailability of the crushed tablets relative to the intact tablets was 156% for the 400-mg strength and 137% for the 600-mg strength.,Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10478991/),%,156,71031,DB01412,Theobromine
,10478991,bioavailability,The bioavailability of the crushed tablets relative to the intact tablets was 156% for the 400-mg strength and 137% for the 600-mg strength.,Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10478991/),%,137,71032,DB01412,Theobromine
,3965236,terminal t1/2,"After intravenous pentoxifylline, plasma levels declined in a biphasic manner, with a terminal t1/2 of 1.63 +/- 0.8 hr.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),h,1.63,71242,DB01412,Theobromine
,3965236,Plasma clearance,Plasma clearance was 1333 +/- 481 ml/min and the volume of distribution was 168 +/- 82.3 l.,Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),[ml] / [min],1333,71243,DB01412,Theobromine
,3965236,volume of distribution,Plasma clearance was 1333 +/- 481 ml/min and the volume of distribution was 168 +/- 82.3 l.,Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),l,168,71244,DB01412,Theobromine
,3965236,bioavailability,"Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),%,20,71245,DB01412,Theobromine
,3965236,bioavailability,"Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),%,30,71246,DB01412,Theobromine
,16721727,tissue-to-serum AUC ratios,"After administration of pentoxifylline, tissue-to-serum AUC ratios ranged from 0.1 for liver and lungs to 0.32 for brain tissue.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.1,79648,DB01412,Theobromine
,16721727,tissue-to-serum AUC ratios,"After administration of pentoxifylline, tissue-to-serum AUC ratios ranged from 0.1 for liver and lungs to 0.32 for brain tissue.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.32,79649,DB01412,Theobromine
,16721727,AUC ratio,The highest value of metabolite-to-parent AUC ratio (4.98) was observed in lungs.,Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,4.98,79650,DB01412,Theobromine
,16721727,tissue-to-serum AUC ratios,"When (-)-(R)-M1 was given as a parent drug, tissue-to-serum AUC ratios in liver, kidney, and lungs were very close and ranged from 0.64 to 0.72.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.64 to 0.72,79651,DB01412,Theobromine
not exceed,16721727,AUC ratios,"In consequence, metabolite-to-parent AUC ratios did not exceed the value of 0.27.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.27,79652,DB01412,Theobromine
,3403100,maximal plasma concentration (Cmax),"After a single oral dose of 400 mg Oxopurin, a mean maximal plasma concentration (Cmax) of 164 +/- 62 micrograms/l was obtained after 2.2 h (tmax).",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),[μg] / [l],164,86546,DB01412,Theobromine
,3403100,tmax,"After a single oral dose of 400 mg Oxopurin, a mean maximal plasma concentration (Cmax) of 164 +/- 62 micrograms/l was obtained after 2.2 h (tmax).",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),h,2.2,86547,DB01412,Theobromine
,3403100,peak plasma concentration,"After an identical dose of Trental-400, a peak plasma concentration of 123 +/- 33 micrograms/l was obtained after 2.4 h.",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),[μg] / [l],123,86548,DB01412,Theobromine
,3403100,relative bioavailability,The mean relative bioavailability of pentoxifylline from Oxopurin was 1.30 +/- 0.19 relative to that of Trental-400.,Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),,1.30,86549,DB01412,Theobromine
,27662634,EPC,"EPC of theobromine was calculated with 3.80 µg/mL, and irrelevant concentrations of theobromine were determined at 8 ng/mL in plasma and at 142 ng/mL in urine.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.80,91484,DB01412,Theobromine
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.20,91485,DB01412,Theobromine
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],6,91486,DB01412,Theobromine
,27662634,IUC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],75,91487,DB01412,Theobromine
,10048796,plasma,Attainable plasma values are 0.7 micromol/l from 80g of black chocolate.,Plasma kinetics in man of epicatechin from black chocolate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10048796/),[μM] / [l],0.7,92857,DB01412,Theobromine
,6700656,Peak serum levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],13.5,94488,DB01412,Theobromine
,6700656,peak levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],8.4,94489,DB01412,Theobromine
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,3.9,94490,DB01412,Theobromine
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,5.8,94491,DB01412,Theobromine
,10850837,bioavailability,Mean bioavailability after oral administration ranged from 15 to 32% among treatment groups and was not affected by the presence of food.,Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850837/),%,15 to 32,94636,DB01412,Theobromine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,79.6,97399,DB01412,Theobromine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,10.8,97400,DB01412,Theobromine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,3.7,97401,DB01412,Theobromine
,19610376,limit of detection,The limit of detection was found to be 5 ng/mL.,Validation of an HPLC method for determination of pentoxifylline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19610376/),[ng] / [ml],5,98025,DB01412,Theobromine
>,19610376,absolute recoveries,The absolute recoveries of pentoxifylline and chloramphenicol from human plasma were >97%.,Validation of an HPLC method for determination of pentoxifylline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19610376/),%,97,98026,DB01412,Theobromine
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,0.75,99617,DB01412,Theobromine
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,0.78,99618,DB01412,Theobromine
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,1.17,99619,DB01412,Theobromine
,31246127,area under the concentration-time curve (AUC),"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[h·μg] / [ml],15.67 to 94.66,100652,DB01412,Theobromine
,31246127,elimination half-life,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),h,0.68 to 0.91,100653,DB01412,Theobromine
,31246127,volume of distribution,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[l] / [kg],0.55 to 0.66,100654,DB01412,Theobromine
,31246127,clearance,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[l] / [h·kg],0.42 to 0.64,100655,DB01412,Theobromine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],942,102658,DB01412,Theobromine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],884,102659,DB01412,Theobromine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],537,102660,DB01412,Theobromine
,30011631,Cmax,"CF was the main methylxanthine found in plasma (Cmax=10.50μM, Tmax=1.2h).",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,10.50,114279,DB01412,Theobromine
,30011631,Tmax,"CF was the main methylxanthine found in plasma (Cmax=10.50μM, Tmax=1.2h).",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),h,1.2,114280,DB01412,Theobromine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,3.36,114281,DB01412,Theobromine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,1.44,114282,DB01412,Theobromine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,1.27,114283,DB01412,Theobromine
,30011631,Cmax,"In 24h urine, eleven methylxanthines and methyluric acids were detected, 1-MU being the major metabolite (Cmax=150.52μM, Tmax=12h) amounting to 67.7% of the total urinary metabolites.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,150.52,114284,DB01412,Theobromine
,30011631,Tmax,"In 24h urine, eleven methylxanthines and methyluric acids were detected, 1-MU being the major metabolite (Cmax=150.52μM, Tmax=12h) amounting to 67.7% of the total urinary metabolites.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),h,12,114285,DB01412,Theobromine
,28704725,flow rate,"LSF, PTX and 3-isobutyl 1-methyl xanthine (IBMX, internal standard) were separated on Inertsil® ODS (C18) column (250×4.6mm, 5μm) with mobile phase consisting of A-methanol B-water (50:50v/v) run in isocratic mode at flow rate of 1mL/min for 15min and detection at 273nm.",Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),[ml] / [min],1,118137,DB01412,Theobromine
,28704725,absolute recoveries,The mean absolute recoveries were found to be 80.47±3.44 and 80.89±3.73% for LSF and PTX respectively.,Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),%,80.47,118138,DB01412,Theobromine
,28704725,absolute recoveries,The mean absolute recoveries were found to be 80.47±3.44 and 80.89±3.73% for LSF and PTX respectively.,Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),%,80.89,118139,DB01412,Theobromine
,19645320,flow rate,"HPLC separation of all compounds was carried out on a normal-phase ChiralPak AD column (250 mm x 4.6 mm i.d., 5 mm), using, as a mobile phase, a mixture of hexane and 2-propanol (84:16, v/v) containing 0.01% of diethylamine with a flow rate of 1.5 mL x min(-1).",Validation of a high-performance liquid chromatography method for pharmacokinetic evaluation of pentoxifylline and lisofylline in rat serum and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645320/),[ml] / [min],1.5,118746,DB01412,Theobromine
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],23.8,125913,DB01412,Theobromine
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],15.0,125914,DB01412,Theobromine
,25663650,intrinsic hepatic clearance,The estimated intrinsic hepatic clearance was 5.427 ml/min and hepatic clearance calculated using the well-stirred model was 1.22 ml/min.,Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663650/),[ml] / [min],5.427,126340,DB01412,Theobromine
,25663650,hepatic clearance,The estimated intrinsic hepatic clearance was 5.427 ml/min and hepatic clearance calculated using the well-stirred model was 1.22 ml/min.,Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663650/),[ml] / [min],1.22,126341,DB01412,Theobromine
,14506595,bioavailable,Pentoxifylline was readily metabolized and bioavailable (50% +/- 26%).,Dosing regimen and hematologic effects of pentoxifylline and its active metabolites in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506595/),%,50,130553,DB01412,Theobromine
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,3.9,130622,DB01412,Theobromine
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,1.6,130623,DB01412,Theobromine
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,5.6,130624,DB01412,Theobromine
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,3.6,130625,DB01412,Theobromine
,10514902,Cmax,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [ml],326.38,134648,DB01412,Theobromine
,10514902,Cmax,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [ml],266.35,134649,DB01412,Theobromine
,10514902,AUC0-t,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [h·ml],2424,134650,DB01412,Theobromine
,10514902,AUC0-t,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [h·ml],2141,134651,DB01412,Theobromine
,10514902,Vss/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],16537,134652,DB01412,Theobromine
,10514902,Vss/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],20136,134653,DB01412,Theobromine
,10514902,Vd/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],11807,134654,DB01412,Theobromine
,10514902,Vd/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],15801,134655,DB01412,Theobromine
,31175387,Effective concentration (EC50),"Effective concentration (EC50) of PTX in RCO was 8.2 nM and plasma PTX level was 7 nM/mL after single oral dosing of 25 mg/kg, which was 1/6th the clinically used dose.",Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175387/),nM,8.2,134987,DB01412,Theobromine
,26925505,drug,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),%,74.9,139891,DB01412,Theobromine
,26925505,entrapment efficiency,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),%,74.9,139892,DB01412,Theobromine
,26925505,elasticity,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),1/[mgs],145,139893,DB01412,Theobromine
,26925505,zeta potential,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),mv,-,139894,DB01412,Theobromine
,26925505,zeta potential,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),mv,34.9,139895,DB01412,Theobromine
,26925505,vesi,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),μm,0.69,139896,DB01412,Theobromine
,26925505,PDI,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),,0.11,139897,DB01412,Theobromine
,26925505,permeation flux,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),1/[(μgcm)^2],56.28,139898,DB01412,Theobromine
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.035,142979,DB01412,Theobromine
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.094,142980,DB01412,Theobromine
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.061,142981,DB01412,Theobromine
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.153,142982,DB01412,Theobromine
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,11.4,142983,DB01412,Theobromine
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,4.3,142984,DB01412,Theobromine
,8735418,elimination half-life,For caffeine the mean elimination half-life was calculated to be 47 h.,Pharmacokinetics of caffeine in the oestrogen-implanted ovariectomized ewe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735418/),h,47,145402,DB01412,Theobromine
,6729831,fraction of,In in vitro and in vivo the fraction of theobromine unbound to plasma proteins averaged 0.90 over a wide range of concentrations.,Kinetics and metabolism of theobromine in male rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6729831/),,0.90,159440,DB01412,Theobromine
,30526026,flow rate,"The analyte and the internal standard were separated from endogenous components on Ace phenyl column using a mixture of 5 mM ammonium acetate buffer and high performance liquid chromatography grade acetonitrile (60:40, v/v) as mobile phase at a flow rate of 1 ml/min.",Development and validation of bioanalytical liquid chromatography-tandem mass spectrometry method for the estimation of pentoxifylline in human plasma: Application for a comparative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30526026/),[ml] / [min],1,162389,DB01412,Theobromine
,11903871,peak blood level,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],5400,165824,DB01412,Theobromine
,11903871,half-life,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),h,15.3,165825,DB01412,Theobromine
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],300,165826,DB01412,Theobromine
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],150,165827,DB01412,Theobromine
,7160423,constant rate,"Subjects were each given either a 25, 50 or 100 mg intravenous loading dose of oxpentifylline followed by an intravenous infusion at a constant rate of 1.5 mg/min for 3 h.",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),,1,167730,DB01412,Theobromine
,7160423,terminal half-life,"The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),h,1.02,167731,DB01412,Theobromine
,7160423,clearance,"The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),[ml] / [min],3 000 to 6 000,167732,DB01412,Theobromine
,7160423,half-life,"The clearance of a reduced metabolite of oxpentifylline was less than that of the intact drug, although the half-life was similar (0.83 +/- 0.18 h).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),h,0.83,167733,DB01412,Theobromine
,8478997,mean residence time,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),h,1.09,168669,DB01412,Theobromine
,8478997,steady-state volume of distribution,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),[l] / [kg],2.81,168670,DB01412,Theobromine
,8478997,clearance,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),[l] / [h·kg],3.06,168671,DB01412,Theobromine
,8478997,Times to peak concentration,Times to peak concentration ranged from 1-10 h for either dose form.,Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),h,1-10,168672,DB01412,Theobromine
,8478997,relative bioavailability (F'),There was no difference in relative bioavailability (F') between whole (0.98 +/- 0.30) and crushed Trental tablets.,Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),,0.98,168673,DB01412,Theobromine
,32318890,globule size,The optimized SNEDDS had a mean globule size of 165 nm with minimal turbidity in an aqueous medium.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),,165,172348,DB01412,Theobromine
,32318890,AUC,Bioavailability of PTX increased 1.5-folds (AUC = 1013.30 ng h/mL) as SNEDDS than the pure drug with an AUC of 673.10 ng h/mL.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),[h·ng] / [ml],1013.30,172349,DB01412,Theobromine
,32318890,AUC,Bioavailability of PTX increased 1.5-folds (AUC = 1013.30 ng h/mL) as SNEDDS than the pure drug with an AUC of 673.10 ng h/mL.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),[h·ng] / [ml],673.10,172350,DB01412,Theobromine
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,8.58,174080,DB01412,Theobromine
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,5.66,174081,DB01412,Theobromine
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.47,174082,DB01412,Theobromine
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.72,174083,DB01412,Theobromine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB01412,Theobromine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB01412,Theobromine
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB01412,Theobromine
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,11,178654,DB01412,Theobromine
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,1.1,178655,DB01412,Theobromine
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,132,178656,DB01412,Theobromine
,12125034,R:S plasma concentration ratio,"In vivo, the R:S plasma concentration ratio of M1 ranged from 0.010-0.025 after intravenous infusion of 300 or 600 mg of pentoxifylline, and from 0.019-0.037 after oral administration of 600 mg.",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),,0.010-0.025,178657,DB01412,Theobromine
,12125034,R:S plasma concentration ratio,"In vivo, the R:S plasma concentration ratio of M1 ranged from 0.010-0.025 after intravenous infusion of 300 or 600 mg of pentoxifylline, and from 0.019-0.037 after oral administration of 600 mg.",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),,0.019-0.037,178658,DB01412,Theobromine
,30219998,terminal elimination half-life,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),h,1.05,182245,DB01412,Theobromine
,30219998,volume of distribution,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),[l] / [kg],6.30,182246,DB01412,Theobromine
,30219998,total body clearance,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),[l] / [h·kg],5.31,182247,DB01412,Theobromine
,2751739,Peak plasma levels of radioactivity,Peak plasma levels of radioactivity (4.1-6.2 micrograms eq ml-1) occurred 0.25-0.75 h after administration.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),[eq·μg] / [ml],4.1-6.2,183909,DB01412,Theobromine
,2751739,initial half-life,This radioactivity decayed in a biexponential fashion with an initial half-life of 1.01 +/- 0.13 h and a terminal half-life of 36.06 +/- 16.94 h.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,1.01,183910,DB01412,Theobromine
,2751739,terminal half-life,This radioactivity decayed in a biexponential fashion with an initial half-life of 1.01 +/- 0.13 h and a terminal half-life of 36.06 +/- 16.94 h.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,36.06,183911,DB01412,Theobromine
,2751739,peak plasma levels,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),[μg] / [ml],0.48-2.25,183912,DB01412,Theobromine
,2751739,initial half-life,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,0.18,183913,DB01412,Theobromine
,2751739,terminal half-life,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,0.76,183914,DB01412,Theobromine
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],10.9,186571,DB01412,Theobromine
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],7.1,186572,DB01412,Theobromine
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.38,186573,DB01412,Theobromine
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.41,186574,DB01412,Theobromine
,21476905,clearance,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [h·kg],0.08,192013,DB01412,Theobromine
,21476905,volume of distribution,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [kg],0.91,192014,DB01412,Theobromine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.24,192015,DB01412,Theobromine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.37,192016,DB01412,Theobromine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.39,192017,DB01412,Theobromine
,627135,half-life (t1/2),"Normal male volunteers on xanthine-restricted diets had a plasma theobromine (TB) half-life (t1/2) of 6.1 +/- 0.7 hr (mean +/- SEM), a TB metabolic clearance rate (MCR) of 113.8 +/- 6.8 ml/min (mean +/- SEM), and an apparent volume of distribution (aVd) of 59.9 +/- 7.8 L (mean +/- SEM) after a single oral dose of 6 mg/kg of TB.",Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627135/),h,6.1,193752,DB01412,Theobromine
,627135,metabolic clearance rate (MCR),"Normal male volunteers on xanthine-restricted diets had a plasma theobromine (TB) half-life (t1/2) of 6.1 +/- 0.7 hr (mean +/- SEM), a TB metabolic clearance rate (MCR) of 113.8 +/- 6.8 ml/min (mean +/- SEM), and an apparent volume of distribution (aVd) of 59.9 +/- 7.8 L (mean +/- SEM) after a single oral dose of 6 mg/kg of TB.",Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627135/),[ml] / [min],113.8,193753,DB01412,Theobromine
,627135,apparent volume of distribution (aVd),"Normal male volunteers on xanthine-restricted diets had a plasma theobromine (TB) half-life (t1/2) of 6.1 +/- 0.7 hr (mean +/- SEM), a TB metabolic clearance rate (MCR) of 113.8 +/- 6.8 ml/min (mean +/- SEM), and an apparent volume of distribution (aVd) of 59.9 +/- 7.8 L (mean +/- SEM) after a single oral dose of 6 mg/kg of TB.",Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627135/),l,59.9,193754,DB01412,Theobromine
,19694503,bioavailability,"Pentoxifylline (PTX) is a highly water-soluble, hemorheologic drug that undergoes first-pass effect with 20% bioavailability.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),%,20,208279,DB01412,Theobromine
,19694503,zeta potential,"The z-average particle size, zeta potential, and EE% of the SLNs were at least 250 nm, -30.2 mV, and 70%, respectively.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),,70,208280,DB01412,Theobromine
,19694503,EE%,"The z-average particle size, zeta potential, and EE% of the SLNs were at least 250 nm, -30.2 mV, and 70%, respectively.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),,70,208281,DB01412,Theobromine
,16343291,elimination half-life (t(1/2el)),"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),h,1.05,210420,DB01412,Theobromine
,16343291,total body clearance,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[l] / [h·kg],1.90,210421,DB01412,Theobromine
,16343291,volume of distribution,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[l] / [kg],2.40,210422,DB01412,Theobromine
,16343291,mean residence time,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),h,2.73,210423,DB01412,Theobromine
,16343291,maximal plasma concentration,"After oral dosing, mean maximal plasma concentration of pentoxyfylline was 4.01 microg/mL and the interval from p.o. administration until maximum concentration was 1.15 h.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[μg] / [ml],4.01,210424,DB01412,Theobromine
,16343291,oral bioavailability,The mean oral bioavailability was found to be 28.2%.,Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),%,28.2,210425,DB01412,Theobromine
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],0.9,217781,DB01412,Theobromine
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],1.4,217782,DB01412,Theobromine
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.5,217783,DB01412,Theobromine
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.3,217784,DB01412,Theobromine
,10877011,elimination half-life,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217785,DB01412,Theobromine
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217786,DB01412,Theobromine
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],4.1,217787,DB01412,Theobromine
,10877011,saliva:plasma concentrations ratio,Excellent correlations were found between saliva and plasma concentrations of caffeine (r2 = 0.98) with a mean saliva:plasma concentrations ratio of 0.7 +/- 0.1.,The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.7,217788,DB01412,Theobromine
,30300750,a,We have synthesized Lisofylline-Linoleic acid (LSF-LA) conjugate which self-assembled into micelles (156.9 nm; PDI 0.187; CMC 1 μg/mL; aggregation number 54) without any surfactant and showed enhanced cellular uptake.,Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300750/),,54,219575,DB01412,Theobromine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],107,226379,DB01412,Theobromine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21,226380,DB01412,Theobromine
,8807660,half-life,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),h,5 to 31,226381,DB01412,Theobromine
,8807660,clearance,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],46 to 9,226382,DB01412,Theobromine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21 to 9,226383,DB01412,Theobromine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],14 to 6,226384,DB01412,Theobromine
,17253910,AUC(0-infinity),"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],5420,234708,DB01412,Theobromine
,17253910,Cmax,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"16,727",234709,DB01412,Theobromine
,17253910,Tmax,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,5,234710,DB01412,Theobromine
,17253910,k(el),"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.036,234711,DB01412,Theobromine
,17253910,t1/2,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,19,234712,DB01412,Theobromine
,17253910,AUC(0-infinity),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],4224,234713,DB01412,Theobromine
,17253910,AUC(0-infinity),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],6824,234714,DB01412,Theobromine
,17253910,Cmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"11,181",234715,DB01412,Theobromine
,17253910,Cmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"16,758",234716,DB01412,Theobromine
,17253910,Tmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,5,234717,DB01412,Theobromine
,17253910,k(el),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.028,234718,DB01412,Theobromine
,17253910,k(el),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.032,234719,DB01412,Theobromine
,17253910,t1/2,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,25,234720,DB01412,Theobromine
,17253910,t1/2,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,22,234721,DB01412,Theobromine
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,675,235228,DB01412,Theobromine
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,852,235229,DB01412,Theobromine
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],84,235230,DB01412,Theobromine
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],107,235231,DB01412,Theobromine
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1309,235232,DB01412,Theobromine
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1027,235233,DB01412,Theobromine
,23871018,total run time,Each sample was run at 0.5 mL/min for a total run time of 7 min/sample.,Simultaneous quantification of caffeine and its three primary metabolites in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23871018/),[min] / [sample],7,235555,DB01412,Theobromine
,10924397,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),h,31.4,244859,DB01412,Theobromine
,10924397,steady state volume of distribution (V(SS)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[l] / [kg],0.62,244860,DB01412,Theobromine
,10924397,total body clearance (Cl(T)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],14.7,244861,DB01412,Theobromine
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.62,244862,DB01412,Theobromine
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.34,244863,DB01412,Theobromine
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,36.0,244864,DB01412,Theobromine
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,39.2,244865,DB01412,Theobromine
,10924397,terminal elimination half-life,"The terminal elimination half-life of the former, estimated in two camels, was 70.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),,70,244866,DB01412,Theobromine
,31647676,polydispersity index,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,0.209,261675,DB01412,Theobromine
,31647676,critical micelle concentration (cmc),"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),[μg] / [ml],5.95,261676,DB01412,Theobromine
,31647676,Nagg,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,14.82,261677,DB01412,Theobromine
,31647676,oral bioavailability,PK of LSF-LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism.,Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),%,74.86,261678,DB01412,Theobromine
,3958905,tmax,"Its metabolites, a secondary alcohol and two homologous carboxylic acids showed tmax values from 0.72 to 1.15 hours.",Pharmacokinetics of orally administered pentoxifylline in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.72 to 1.15,266207,DB01412,Theobromine
,3958905,apparent plasma half-life,The apparent plasma half-life of pentoxifylline varied between 0.39 and 0.84 hours for the various doses while the apparent half-lives of the metabolites were in the range of 0.96 to 1.61 hours.,Pharmacokinetics of orally administered pentoxifylline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.39 and 0.84,266208,DB01412,Theobromine
,3958905,apparent half-lives,The apparent plasma half-life of pentoxifylline varied between 0.39 and 0.84 hours for the various doses while the apparent half-lives of the metabolites were in the range of 0.96 to 1.61 hours.,Pharmacokinetics of orally administered pentoxifylline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.96 to 1.61,266209,DB01412,Theobromine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.6,267752,DB01412,Theobromine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.7,267753,DB01412,Theobromine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.9,267754,DB01412,Theobromine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.0,267755,DB01412,Theobromine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.1,267756,DB01412,Theobromine
,28903089,run time,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,5,267757,DB01412,Theobromine
,22648913,Cmax,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[ng] / [ml],140.6,272580,DB01412,Theobromine
,22648913,Cmax,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[ng] / [ml],132.6,272581,DB01412,Theobromine
,22648913,AUC0-24,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[h·ng] / [ml],986.4,272582,DB01412,Theobromine
,22648913,AUC0-24,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[h·ng] / [ml],1 035.8,272583,DB01412,Theobromine
,8255998,Peak concentrations,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),[μg] / [ml],10,272590,DB01412,Theobromine
,8255998,Peak concentrations,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),[μg] / [ml],100,272591,DB01412,Theobromine
,8255998,elimination half-lives,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),min,4.6,272592,DB01412,Theobromine
,8255998,elimination half-lives,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),min,7.5,272593,DB01412,Theobromine
